Gentium S.p.a. (GENT) Return on Equity ROE from the fourth quarter 2013 to fourth quarter 2012 and annually, average high and low, overall ranking from Dec 31 2013 to Dec 31 2012 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gentium S.p.a.  (GENT)

Gentium S.p.a.'s ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Gentium S.p.a. in the fourth quarter 2013?
Gentium S.p.a. achieved a return on average equity (ROE) of 131.02 % in its fourth quarter 2013, this is above GENT's average return on equity of -42.88%.
Gentium S.p.a. shareholder's equity over the 12 months ending in its fourth quarter 2013 are valued at $26 million

ROE has advanced compared to -128.38% in the third quarter 2013, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 7 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2013 from 0 to 296.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2013)
IV. Quarter		 0
III. Quarter		 (Jun 30 2013)
II. Quarter		 0
I. Quarter		 (Dec 31 2012)
FY
Y / Y Equity Change -8.68 % 4.91 % 41.37 % 42.83 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 35 -35 -34 -64 -62
Return On Equity (TTM) 131.02 % -128.38 % -125.82 % -262.32 % -277.53 %
GENT's Total Ranking # 296 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 25 25 32 25 27
Seq. Equity Change 0 % -23.14 % 30.1 % -8.68 % 14.88 %
Seq. Net Income Change - - - - -

Back to GENT Management Effectiveness >> GENT's 5 Years Annual ROE >> Compare GENT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 8
Sector # 28
Overall # 296

Return On Equity Statistics
High Average Low
49.99 %
-42.88 %
-135.74 %
(Dec 31 2013)   (Dec 31 2012)





GENT Annual Return On Equity (Dec 31 2013)
2013		 (Dec 31 2012)
2012		 (Dec 31 2009)
2011

Total Equity in Millions 49 27 17 0 0
Y / Y Equity Change 83.41 % 56.4 % - - -
Net Income in Millions 25 -36 -6 0 0
Y / Y Net Income Change - - - - -
Return On Equity 49.99 % -135.74 % -36.75 % - -

Back to GENT Management Effectiveness >> GENT's 5 Years Annual ROE >> Compare GENT ROE to its Competitors




Annual Roe Comment
In 2013 ROE improved to 49.99 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GENT's' Return on Equity at Yahoo Finance
GENT's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GENT's Competitors
Subscribers only: Roe for Gentium S.p.a.'s Suppliers
Subscribers only: Return On Equity for GENT's Customers




Companies with similar Return On Equity at Dec 31 2013, within Healthcare Sector ROE
Lftd Partners Inc   343.63 %
Agios Pharmaceuticals Inc   247.29 %
Epizyme Inc.  208.50 %
Biocorrx Inc   193.53 %
Cadence Pharmaceuticals Inc  173.34 %
Bluebird Bio Inc   171.14 %
Arena Pharmaceuticals Inc   168.05 %
Cyclo Therapeutics Inc   156.17 %
Brainstorm Cell Therapeutics inc   149.47 %
Filana Therapeutics Inc   139.98 %
Abbvie Inc   113.22 %
Savara Inc   108.06 %
Encompass Health Corporation  99.91 %
Portola Pharmaceuticals inc   96.66 %
Sorrento Therapeutics Inc   87.21 %
Guided Therapeutics Inc   81.53 %
Oramed Pharmaceuticals Inc  68.52 %
China Yct International Group, Inc.  67.98 %
Bausch Health Companies Inc   66.44 %
Viskase Holdings inc   61.25 %
Fonar Corporation  56.31 %
Lightwave Logic Inc   52.49 %
Gentium S.p.a.  49.99 %
Insys Therapeutics, Inc.  46.69 %
Milestone Scientific Inc   44.48 %
Assertio Holdings inc   44.11 %
Veru Inc   42.53 %
Bard C R Inc  39.12 %
Remedent Inc   36.90 %
Mettler toledo International Inc   36.07 %

Date modified: 2026-09-10T02:29:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.